Cormedix (HAM:19KA) ROE % Adjusted to Book Value: 31.00% (As of Mar. 2026)


HAM:19KA Cormedix Inc HAM:19KA
39 GF Score
Price €6.65
GF Value €57.74
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix ROE % Adjusted to Book Value?

Cormedix HAM:19KA +2.25% 39 ROE % Adjusted to Book Value is 31.00% as of Mar. 2026. GuruFocus rates HAM:19KA with a GF Score™ of 39/100 and a GF Value™ of €57.74 (Possible Value Trap). The stock has 6 warning signs investors should review.

Cormedix's ROE % for the quarter that ended in Mar. 2026 was 36.89%. Cormedix's PB Ratio for the quarter that ended in Mar. 2026 was 1.19. Cormedix's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 31.00%.

Cormedix ROE % Adjusted to Book Value Related Terms

Cormedix ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Cormedix's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cormedix ROE % Adjusted to Book Value Chart

Cormedix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 26.41

Cormedix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 5.83 31.00

HAM:19KA vs STTK, ACHV, EIKN: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Cormedix's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cormedix ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cormedix's ROE % Adjusted to Book Value falls into.


HAM:19KA
39GF Score
Cormedix Inc HAM:19KA
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cormedix ROE % Adjusted to Book Value Calculation

Cormedix's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=65.23% / 2.47
=26.41%

Cormedix's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=36.89% / 1.19
=31.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 31.00% mean?
Cormedix (HAM:19KA) has a ROE % Adjusted to Book Value of 31.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cormedix and its competitors.
Is Cormedix's ROE % Adjusted to Book Value too high?
Cormedix's current ROE % Adjusted to Book Value is 31.00%. Overall, Cormedix has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cormedix's ROE % Adjusted to Book Value compare to STTK and ACHV?
Cormedix's ROE % Adjusted to Book Value of 31.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cormedix and its competitors. Cormedix's current ROE % Adjusted to Book Value is 31.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cormedix stock overvalued right now?
Based on GuruFocus' analysis, Cormedix (HAM:19KA) is currently considered Possible Value Trap. The stock's GF Value™ is €57.74, compared to a current price of €6.65 — trading 88.5% below its estimated fair value. The current ROE % Adjusted to Book Value is 31.00%. Cormedix's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Cormedix (HAM:19KA), the current ROE % Adjusted to Book Value is 31.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cormedix (HAM:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €6.65 is trading 88.5% below its estimated GF Value™ of €57.74. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for HAM:19KA:

  • ROE % Adjusted to Book Value: 31.00%
  • GF Value™: €57.74 vs. price of €6.65 (88.5% below fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cormedix Business Description

Other Exchanges CRMD:USA19KA:Germany
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
39GF Score

Get the complete analysis for HAM:19KA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.65
Price
€57.74
GF Value